



HAL
open science

New Antimalarial and Antimicrobial Tryptamine Derivatives from the Marine Sponge *Fascaplysinopsis reticulata*

Pierre-Éric Campos, Emmanuel Pichon, Céline Moriou, Patricia Clerc, Rozenn Trepos, Michel Frédérich, Nicole de Voogd, Claire Hellio, Anne Gauvin-Bialecki, Ali Al-Mourabit

► **To cite this version:**

Pierre-Éric Campos, Emmanuel Pichon, Céline Moriou, Patricia Clerc, Rozenn Trepos, et al.. New Antimalarial and Antimicrobial Tryptamine Derivatives from the Marine Sponge *Fascaplysinopsis reticulata*. *Marine drugs*, 2019, 17 (3), pp.167. 10.3390/md17030167 . hal-02339783

HAL Id: hal-02339783

<https://hal.science/hal-02339783>

Submitted on 31 Oct 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Article

New Antimalarial and Antimicrobial Tryptamine Derivatives from the Marine Sponge *Fascaplysinopsis reticulata*

Pierre-Eric Campos ¹, Emmanuel Pichon ¹, Céline Moriou ², Patricia Clerc ¹, Rozenn Trépos ³, Michel Frederich ⁴, Nicole De Voogd ⁵, Claire Hellio ³, Anne Gauvin-Bialecki ^{1,*} and Ali Al-Mourabit ²

¹ Laboratoire de Chimie des Substances Naturelles et des Sciences des Aliments, Faculté des Sciences et Technologies, Université de La Réunion, 15 Avenue René Cassin, CS 92003, 97744 Saint-Denis CEDEX 9, La Réunion, France; pierre-eric.campos@univ-reunion.fr (P.-E.C.); pichon.manu@orange.fr (E.P.); patricia.clerc@univ-reunion.fr (P.C.)

² Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Univ. Paris-Sud, Université Paris-Saclay, 1, av. de la Terrasse, 91198 Gif-sur-Yvette, France; Celine.Moriou@cnrs.fr (C.M.); Ali.ALMOURABIT@cnrs.fr (A.A.-M.)

³ Laboratoire des Sciences de l'Environnement MARin (LEMAR), Université de Brest, CNRS, IRD, Ifremer, LEMAR, F-29280 Plouzane, France; rozenn.trepos@port.ac.uk (R.T.); Claire.Hellio@univ-brest.fr (C.H.)

⁴ Laboratory of Pharmacognosy, Center for Interdisciplinary Research on Medicines, CIRM, University of Liège B36, 4000 Liège, Belgium; M.Frederich@ulg.ac.be

⁵ Naturalis Biodiversity Center, Darwinweg 2, 2333 CR Leiden, The Netherlands; nicole.devoogd@naturalis.nl

* Correspondence: anne.bialecki@univ-reunion.fr; Tel.: +262-26293-8197

Received: 22 February 2019; Accepted: 12 March 2019; Published: 15 March 2019



Abstract: Chemical study of the CH₂Cl₂-MeOH (1:1) extract of the sponge *Fascaplysinopsis reticulata* collected in Mayotte highlighted three new tryptophan derived alkaloids, 6,6'-bis-(debromo)-gelliisine F (1), 6-bromo-8,1'-dihydro-isoplysin A (2) and 5,6-dibromo-8,1'-dihydro-isoplysin A (3), along with the synthetically known 8-oxo-tryptamine (4) and the three known molecules from the same family, tryptamine (5), (*E*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (6) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (7). Their structures were elucidated by 1D and 2D NMR spectra and HRESIMS data. All compounds were evaluated for their antimicrobial and their antiplasmodial activities. Regarding antimicrobial activities, the best compounds are (2) and (3), with minimum inhibitory concentration (MIC) of 0.01 and 1 µg/mL, respectively, towards *Vibrio natrigens*, and (5), with MIC values of 1 µg/mL towards *Vibrio carchariae*. In addition the known 8-oxo-tryptamine (4) and the mixture of the (*E*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (6) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (7) showed moderate antiplasmodial activity against *Plasmodium falciparum* with IC₅₀ values of 8.8 and 8.0 µg/mL, respectively.

Keywords: *Fascaplysinopsis reticulata*; marine sponge; tryptamine alkaloids; antimalarial activity; antimicrobial activity

1. Introduction

Tryptophan-derived alkaloids are well-established bioactive metabolites and have been isolated from various marine organisms: sponges, scleratinian corals, one sea anemone and one nudibranch [1]. Species of the sponge genus *Fascaplysinopsis* have yielded several bioactive tryptophan alkaloids reported to exhibit cytotoxic activity against several cancer cell lines [2,3], antimicrobial [2], antiviral [4] and antimalarial [5] activities.

In our continuing search for bioactive metabolites from marine invertebrates, the sponge *Fascaplysinopsis reticulata* (Hentschel, 1912) from the Dictyoceratida order was investigated. Previous studies on *Fascaplysinopsis reticulata* collected from the Benga Lagoon of the Fiji Islands by Jiménez et al. [6], and then from Indonesia (Molucca Sea) and from the Fiji Islands by Segreaves et al. [7], led to the isolation of 23 alkaloids from the fascaplysin family. More recent study on *Fascaplysinopsis reticulata* collected from Xisha Island (China) by Wang et al. led to the isolation of a pair of bisheterocyclic quinolineimidazole alkaloids, (+)- and (–)-spiroreticulatine [8]. All of the isolated 25 molecules are tryptophane-derived alkaloids.

Our chemical investigation of the extract of *Fascaplysinopsis reticulata* collected in Mayotte (Indian Ocean), led to the isolation of three new members of the tryptophan family, 6,6'-bis-(debromo)-gelliusine F (**1**), 6-bromo-8,1'-dihydro-isoplysin A (**2**) and 5,6-dibromo-8,1'-dihydro-isoplysin A (**3**), along with the known derivatives 8-oxo-tryptamine (**4**), tryptamine (**5**), (*E*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (**6**) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (**7**). The 8-oxo-tryptamine (**4**) was known as synthetic compound [9], but was isolated here from a natural source. We report herein the purification and structure elucidation by spectral data including HRESIMS, 2D NMR and comparison with published data. The biological evaluations of the latter new compounds are described as well.

2. Results and Discussion

2.1. Chemistry

The CH₂Cl₂-MeOH extract of the lyophilized sponge *Fascaplysinopsis reticulata* was first subjected to a reverse-phase silica gel column chromatography to yield fractions. The fractions were subjected to repetitive reverse-phase semi-preparative and analytical HPLC to yield eight compounds (**1**–**7**) (Figure 1). Three were new: one 6,6'-bis-(debromo)-gelliusine F (**1**) and two aplysinopsin derivatives **2** and **3**, described below. In addition to the new compounds, four other known members were identified as 8-oxo-tryptamine (**4**), tryptamine (**5**) and a mixture of (*E*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (**6**) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (**7**) by comparison with published spectroscopic data.

6,6'-bis-(debromo)-gelliusine F (**1**) was obtained as a brown oil. The molecular formula, C₂₀H₂₃N₄, was established from HRESIMS molecular ion peak at *m/z* 319.2013 [M + H]⁺. Analysis of the 1D and 2D ¹H, and ¹³C NMR data for **1** (CD₃OD, Table 1) revealed resonances and correlations (Figure 2) consistent with those of a bis-tryptamine structure linked by the carbons C-2 and C-8', like gelliusine F [10,11]. Analysis of the HSQC correlations and the comparison with latter compounds pointed the fragment C-8, C-9, C-9' (δ H 3.23, 3.00, 3.83–3.69; δ C 23.7, 41.4, 44.3), one aliphatic methine C-8' (δ H 5.10; δ C 34.3), nine aromatic methines C-4, C-5, C-6, C-7, C-2', C-4', C-5', C-6', C-7' (δ H 7.54, 7.38, 7.12, 7.06, 7.27, 7.58, 7.41, 7.14, 7.06; δ C 118.9, 112.6, 123.1, 120.7, 124.0, 119.3, 112.9, 123.3, 120.6) and seven nonprotonated aromatic carbons C-2, C-3, C-3a, C-7a, C-3', C-3a', C-7a' (δ C 124.0, 113.8, 127.5, 135.3, 113.7, 129.2, 138.0). Compound **1** was different from gelliusine F by the presence of the two aromatic methines C-6 and C-6' instead of two nonprotonated aromatic carbons substituted by bromine. Analysis of the COSY correlations revealed the presence of the spin systems C-4–C-5–C-6–C-7 and C-4'–C-5'–C-6'–C-7' and confirmed this difference. These COSY correlations, in addition to the HMBC correlations between H-4 and C-7a, between H-5 and C-3a, between H-6 and C-7a, between H-2', C-3', C-3a' and C-7a', between H-4' and C-7a', between H-5' and C-3a', between H-6' and C-7a' and between H-7' and C-3a', confirmed the presence of two indole cores, the first one substituted in C-2 and C-3 and the second one substituted in C-3'. The COSY correlation between H-8 and H-9 and the HMBC correlation between H-9 and C-3 and between H-8, C-2, C-3 and C-3a indicated the substitution of the first indole core by an ethylamine chain in C-3. The COSY correlation between H-8' and H-9' and the HMBC correlations between H-9' and C-3' and between H-8', C-2', C-3' and C-3a' indicated the substitution of the second indole core by an ethylamine chain in C-3'. The two

tryptamine patterns were linked between C-2 and C-8' like gelliusine F. Compound **1** was named 6,6'-bis-(debromo)-gelliusine F according to gelliusine F, reported in 1995 [11].




Figure 1. Chemical structures of compounds 1–7.

Table 1. 1D and 2D NMR spectroscopic data (^1H , ^{13}C 300 MHz, CD_3OD) for 6,6'-bis-(debromo)-gelliusine F (**1**).

Position	δC , Type	δH (J in Hz)	COSY (^1H - ^1H)	HMBC (^1H - ^{13}C)
2	124.0, C	-	-	-
3	113.8, C	-	-	-
3a	127.5, C	-	-	-
4	118.9, CH	7.54, d (7.8)	5	6, 7a
5	112.6, CH	7.38, m	4, 6	3a, 7
6	123.1, CH	7.12, m	5, 7	4, 7a
7	120.7, CH	7.06, m	6	3a, 5
7a	135.3, C	-	-	-
8	23.7, CH_2	3.23, m	9	2, 3, 3a, 9
9	41.4, CH_2	3.00, m	8	3, 8
2'	124.0, CH	7.27, s	-	3', 3a', 7a'
3'	113.7, C	-	-	-
3a'	129.2, C	-	-	-
4'	119.3, CH	7.58, d (7.8)	5'	6', 7a'
5'	112.9, CH	7.41, m	4', 6'	3a', 7'
6'	123.3, CH	7.14, m	5', 7'	4', 7a'
7'	120.6, CH	7.06, m	6'	3a', 5'
7a'	138.0, C	-	-	-
8'	34.3, CH	5.10, t (8.6)	9'	2', 3', 3a', 9'
9'	44.3, CH_2	3.83–3.69 (m)	8'	3', 8'




Figure 2. Key COSY and HMBC correlations for compounds 1 and 2.

6-bromo-8,1'-dihydro-isoplysin A (2) was obtained as a yellow oil. Its molecular formula, $C_{14}H_{16}BrN_4O$ (9 degree of unsaturation), was established from HRESIMS pseudo-molecular ion peak at m/z 337.0483 (see Supplementary Materials) indicating the presence of one bromine atom in the molecule. Analysis of the 1D and 2D 1H , and ^{13}C NMR data for 2 (CD_3OD , Table 2) revealed resonances and correlations (Figure 2) consistent with those of a 1',8-dihydroaplysinopsin structure: the HSQC correlations revealed the presence of one methylene C-8 (δH 3.35; δC 28.1), one aliphatic methine C-1' (δH 4.62; δC 61.8), four aromatic methines C-2, C-4, C-5, C-7 (δH 7.11, 7.51, 7.14, 7.50; δC 126.4, 121.1, 123.3, 115.5), four nonprotonated aromatic carbons C-3, C-3a, C-6, C-7a (δC 109.0, 127.6, 116.6, 138.1), one guanidine-like carbon C-3' (δC 159.2) and one amide carbonyl C-5' (δC 174.9). The structure of the indole core was determined by the analysis of COSY correlations between H-4 and H-5, the 4J coupling constant between H-5 and H-7 ($J = 1.8$ Hz) and HMBC correlations between H-2, C-3, C-3a, and C-7a, between H-4, C-6 and C-7a and between H-5, C-3a and C-7. The HMBC correlation between H-2 and C-8 indicated the substitution of the non-protonated carbon C-3 by the methylene C-8. The COSY correlation between H-8 and H-1' indicated link between the heterocycle core and C-8. The structure of the heterocycle core was determined by the HMBC correlations between H-1' and C-5', between CH_3 -6' and C-3' and between CH_3 -7', C-3' and C-5'.

Table 2. 1D and 2D NMR spectroscopic data (1H , ^{13}C 300 MHz, CD_3OD) for 6-bromo-8,1'-dihydro-isoplysin A (2).

Position	δC , Type	δH (J in Hz)	COSY (1H - 1H)	HMBC (1H - ^{13}C)
2	126.4, CH	7.11, s	-	3, 3a, 7a, 8
3	109.0, C	-	-	-
3a	127.6, C	-	-	-
4	121.1, CH	7.51, d (8.6)	5	6, 7a
5	123.3, CH	7.14, dd (8.6, 1.8)	4	3a, 7
6	116.6, C	-	-	-
7	115.5, CH	7.50, d (1.8)	-	3a, 5
7a	138.1, C	-	-	-
8	28.1, CH_2	3.35, m	1'	-
1'	61.8, CH	4.62, t (4.9)	8	5', 8
3'	159.2, C	-	-	-
5'	174.9, C	-	-	-
6'	25.9, CH_3	2.90, s	-	3'
7'	29.3, CH_3	2.86, s	-	3', 5'

5,6-dibromo-8,1'-dihydro-isoplysin A (3) was obtained as a yellow oil. Its molecular formula $C_{14}H_{15}Br_2N_4O$ (9 degrees of unsaturation), was established from HRESIMS pseudo-molecular ion peak at m/z 414.9630 (see Supplementary Materials) indicating the presence of two bromine atom in the molecule. Analysis of the 1H and ^{13}C NMR data for 3 and comparison with the 1H and ^{13}C NMR data for 2 (CD_3OD , Table 3) revealed a 1',8-dihydroaplysinopsin structure close to the above-described 6-bromo-8,1'-dihydro-isoplysin A (2), where one hydrogen was replaced by a bromine

atom. The spectra showed two *N*-methyles C-6', C-7' (δ H 2.86, 2.94; δ C 25.4, 28.9), one methylene C-8 (δ H 3.73; δ C 28.2), one aliphatic methine C-1' (δ H 4.60; δ C 61.4), three aromatic methines C-2, C-4, C-7 (δ H 7.16, 7.96, 7.69; δ C 126.6, 123.6, 117.4), five nonprotonated aromatic carbons C-3, C-3a, C-5, C-6, C-7a (δ C 109.0, 129.8, 116.9, 115.9, 137.5), one guanidine-like carbon C-3' (δ C 157.9) and one amide carbonyl C-5' (δ C 175.8). 5,6-dibromo-8,1'-dihydro-isoplysin A (**3**) differed from 6-bromo-8,1'-dihydro-isoplysin A (**2**) by the presence of one more aromatic nonprotonated aromatic carbon and one less aromatic methine. The chemical shifts and the multiplicity of C-4 and C-7 also differed between compound **3** (two singlets) and compound **2** (two doublets). For compound **3**, the multiplicity of C-4 and C-7 indicated that H-4 was *para* to H-7. These spectroscopic features, as well as the molecular formula, supported that the position of the proton H-5 of **2** was substituted by a bromine in compound **3**.

Table 3. Comparison of 1D NMR Spectroscopic Data (^1H , ^{13}C 300 MHz, CD_3OD for (**2**) and ^1H 500 MHz, ^{13}C 600 MHz, CD_3OD for (**3**)) between 6-bromo-8,1'-dihydro-isoplysin A (**2**) and 5,6-dibromo-8,1'-dihydro-isoplysin A (**3**).

Position	δ H (J in Hz)		δ C, Type	
	6-Bromo-8,1'-dihydro-isoplysin A (2)	5,6-Dibromo-8,1'-dihydro-isoplysin A (3)	6-Bromo-8,1'-dihydro-isoplysin A (2)	5,6-Dibromo-8,1'-dihydro-isoplysin A (3)
2	7.11, s	7.16, s	126.4, CH	126.6, CH
3	-	-	109.0, C	109.0, C
3a	-	-	127.6, C	129.8, C
4	7.51, d (8.6)	7.96, s	121.1, CH	123.6, CH
5	7.14, dd (8.6, 1.8)	-	123.3, CH	116.9, C
6	-	-	116.6, C	115.9, C
7	7.50, d (1.8)	7.69, s	115.5, CH	117.4, CH
7a	-	-	138.1, C	137.5, C
8	3.35, m	3.73, m	28.1, CH_2	28.2, CH_2
1'	4.62, t (4.9)	4.60, t (5.3)	61.8, CH	61.4, CH
3'	-	-	159.2, C	157.9, C
5'	-	-	174.9, C	175.8, C
6'	2.90, s	2.86, s	25.9, CH_3	25.4, CH_3
7'	2.86, s	2.94, s	29.3, CH_3	28.9, CH_3

2.2. Microfouling Activity

The capacity of compounds to interfere with microfouling was assessed by screening the pure compounds against five bacterial strains that are involved in the initial formation of the fouling biofilm: *Shewanella putrefaciens*, *Roseobacter litoralis*, *Vibrio carchariae*, *Vibrio natrigens* and *Vibrio proteolyticus*. The effects on both adhesion and growth (A and G) were studied, and the results expressed as the minimal inhibitory concentration (MIC) are summarized in Table 4. The two new 6-bromo-8,1'-dihydro-isoplysin A (**2**) and 5,6-dibromo-8,1'-dihydro-isoplysin A (**3**) showed promising antifouling activity against *Vibrio natrigens*, with MIC values of 0.01 and 1.00 $\mu\text{g}/\text{mL}$, respectively, towards growth inhibition. *Vibrio natrigens* is a major component of biofilms due to its fast generation doubling time, its biofilm producing ability and steel corrosion behavior. Thus, it has considerable negative economic impacts on man-made immersed surfaces [12,13].

The activity of these compounds was lower towards inhibition of adhesion (respectively 100 and $>100 \mu\text{g}/\text{mL}$ for (**2**) and (**3**)). Based on MICs values and mode of action, 6-bromo-8,1'-dihydro-isoplysin A (**2**) is the most potent compound as it has the ability to reduce growth when used at very low concentration and can also affect adhesion at higher doses. Regarding the known compound, tryptamine (**5**) showed promising antimicrobial activity against *Vibrio carchariae* with MIC value of 1 $\mu\text{g}/\text{mL}$. This result is of high interest, as *Vibrio carchariae* is responsible for mass mortalities of fish [14] and invertebrates [15]. Thus, *Vibrio carchariae* is considered to be a major nuisance for the aquaculture sector [16], and new ways to stop its development are sought after.

Table 4. Antimicrobial activities in vitro for pure isolated natural products.

Compounds	<i>Shewanella putrefaciens</i> MIC, µg/mL		<i>Roseobacter littoralis</i> MIC, µg/mL		<i>Vibrio carchariae</i> MIC, µg/mL		<i>Vibrio natrigens</i> MIC, µg/mL		<i>Vibrio proteolyticus</i> MIC, µg/mL	
	A	G	A	G	A	G	A	G	A	G
6,6'-bis-(debromo)-gelliusine F (1)	-	-	-	-	-	-	-	-	-	-
6-bromo-8,1'-dihydro-isoplysin A (2)	-	100	-	-	100	-	100	0.01	-	-
5,6-dibromo-8,1'-dihydro-isoplysin A (3)	-	-	-	-	-	-	-	1	-	-
8-oxo-tryptamine (4)	-	-	-	-	-	-	-	-	-	-
tryptamine (5)	-	-	-	-	-	1	-	-	-	-
(E) and (Z)-6-bromo-2'-demethyl-3'-N-methylaplysinopsin (6 + 7)	-	-	-	-	-	-	-	-	-	-

A: Adhesion inhibition; G: Growth inhibition.

2.3. Antiplasmodial Activity

All the isolated compounds were also tested against the protozoan parasite *Plasmodium falciparum* (3D7 strain). The 8-oxo-tryptamine (4) and the mixture of the known (E) and (Z)-6-bromo-2'-demethyl-3'-N-methylaplysinopsin (6, 7) exhibited antiplasmodial activity against *Plasmodium falciparum* with IC₅₀ values of 8.8 and 8.0 µg/mL respectively while 6,6'-bis-(debromo)-gelliusine F (1), 6-bromo-8,1'-dihydro-isoplysin A (2), 5,6-dibromo-8,1'-dihydro-isoplysin A (3) and tryptamine (5) did not show significant antimalarial activity. Hu et al. [17] have already reported the antiplasmodial activity of (E) and (Z)-6-bromo-2'-demethyl-3'-N-methylaplysinopsin (6, 7) together with the activity of two other aplysinopsins, isoplysin A and 6-bromoaplysinopsin isolated from the sponge *Smenospongia aurea*. Bialonska et Zjawiony [1] also reported, for 27 aplysinopsins, their biological activities, among which the antiplasmodial activity seems to be dependent on the skeleton: all the aplysinopsins that presented antiplasmodial activity had a double bond between C-8 and C-1'. The lack of antiplasmodial activity for compounds (2) and (3) confirms this study. These activities are moderate compared to control drugs, but these simple molecular scaffolds could be investigated for further pharmacomodulations in order to improve final bioactivity.

3. Materials and Methods

3.1. General Experiment Procedures

Optical rotations were measured on a MCP 300 polarimeter (Anton Paar, Les Ulis, France) at 25 °C (MeOH, *c* in g/100 mL). ¹H and ¹³C NMR data were acquired with a Bruker UltraShield Avance-300 and 600 MHz spectrometers (CNRS-ICSN, Bruker, Wissembourg, France). Chemical shifts were referenced using the corresponding solvent signals (δ_H 3.31 and δ_C 49.00 for CD₃OD). The spectra were processed using TopSpin software (TopSpin 3.5, Bruker, Wissembourg, France). HRESIMS spectra were recorded using a Waters Acquity BEH C18, 1.7 µm, 50 × 2.1 mm column on a Waters Micromass LCT-Premier TOF mass spectrometer (Waters, Guyancourt, France) with a Waters Acquity UPLC system.

The sponge was lyophilized with Cosmos –80 °C CRYOTEC and extracted with Dionex ASE 300. Reversed phase column chromatography separations were carried out on glass column (150 × 10 mm i.d.) packed with Acros Organics C18-RP, 23% C, silica gel (40–63 µm). Precoated TLC sheets of silica gel 60, Alugram SIL G/UV254 were used, and spots were visualized on the basis of the UV absorbance at 254 nm and by heating silica gel plates sprayed with formaldehyde–sulfuric acid or Dragendorff reagents. Analytical HPLC was carried out using a Waters Sunfire C₁₈ (150 × 4.6 mm i.d., 5 µm) column and was performed on an Agilent 1100 series system controller equipped with a photodiode array detector (Serie Agilent 1100 G1315B, Agilent Technologies, Wilmington, Germany) and a mass spectrometer detector (Serie Agilent 1100 G1956A, Agilent Technologies, Wilmington, Germany) with

Chemstation software (Version B.04.03. Agilent Technologies, Wilmington, Germany). Preparative HPLC was carried out using a Waters Sunfire Prep RP₁₈ (150 × 19 mm i.d., 5 μm) column and was performed on a Waters 600 system controller equipped with a photodiode array detector (Waters 2996, Waters, Guyancourt, France). Semi-preparative HPLC was carried out using Waters Sunfire Prep RP₁₈ (250 × 10 mm i.d., 5 μm) column and was performed on a Waters 600 system controller (Waters, Guyancourt, France) equipped with photodiode array detectors (Waters 2996 and Waters 486). All solvents were analytical or HPLC grade and were used without further purification.

3.2. Animal Material

The sponge *Fascaplysinopsis reticulata* (phylum Porifera, class Demospongiae, order Dictyoceratida, family Thorectidae) was collected in May 2013 in Passe Bateau, Mayotte (12°58,653' S, 44°58,949' E at 15–17 m depth). One voucher specimen (RMNH POR 8466) was deposited in Naturalis, the Netherlands Centre for Biodiversity. Sponge samples were frozen immediately and kept at −20 °C until processed.

3.3. Extraction and Isolation

The frozen sponge (28 g, dry weight) was chopped into small pieces and extracted by ASE first with Water (×1) and then with MeOH/CH₂Cl₂ (1:1, *v:v*) (×2). After evaporating the solvents under reduced pressure, a brown, oily residue (2.91 g) was obtained. The extract (2.90 g) was then subjected to fractionation by C-18 SPE, eluted with a combination of Water, MeOH and CH₂Cl₂ of decreasing polarity and twelve fractions were obtained (F1–F12).

Fraction F3 (543 mg). Separation of only 100 mg of this fraction was performed by preparative HPLC (Waters Sunfire Prep C₁₈ Column, 5 μm, 150 × 19 mm i.d., 18 mL min^{−1} gradient elution with 2% ACN-H₂O (+0.1% formic acid) over 5 min, then 10% ACN-H₂O (+0.1% formic acid) to 100% ACN over 30 min; UV 280 nm) to furnish pure compound **1** (6,6'-bis-(debromo)-gelliusine F, 0.6 mg).

Fraction F4 (355.4 mg). Only 200 mg was subjected to preparative HPLC (Waters Sunfire Prep C₁₈ Column, 5 μm, 150 × 19 mm i.d., 18 mL min^{−1} gradient elution with 2% ACN-H₂O (+0.1% formic acid) over 5 min, then 2% ACN-H₂O (+0.1% formic acid) to 100% ACN (+0.1% formic acid) over 35 min; UV 280 nm) to give pure compounds **2** (6-bromo-8,1'-dihydro-isoplysin A, 4 mg), **3** (5,6-dibromo-8,1'-dihydro-isoplysin A, 4 mg) and **5** (tryptamine, 4.0 mg).

Fraction F5 (99.1 mg) was subjected to preparative HPLC (Waters Sunfire Prep C₁₈ Column, 5 μm, 150 × 19 mm i.d., 18 mL min^{−1} gradient elution with 2% ACN-H₂O (+0.1% formic acid) over 5 min, then 2% ACN-H₂O (+0.1% formic acid) to 100% ACN (+0.1% formic acid) over 45 min; UV 280 nm) to give pure compound **1** (6,6'-bis-(debromo)-gelliusine F, 1.5 mg), **4** (8-oxo-tryptamine, 0.7 mg) and **5** (tryptamine, 3.0 mg).

Fraction F6 (51.1 mg) was subjected to semi-preparative HPLC (Waters Sunfire Prep RP₁₈ Column, 5 μm, 250 × 10 mm i.d., 4.5 mL min^{−1} gradient elution with 2% ACN-H₂O (+0.1% formic acid) over 5 min, then 2% ACN-H₂O (+0.1% formic acid) to 100% ACN (+0.1% formic acid) over 35 min; UV 280 nm) to give pure compounds **2** (6-bromo-8,1'-dihydro-isoplysin A, 1.2 mg), **4** (8-oxo-tryptamine, 0.4 mg) and **5** (tryptamine, 0.6 mg).

Fraction F7 (266.8 mg) was subjected to semi-preparative HPLC (Waters Sunfire Prep RP₁₈ Column, 5 μm, 250 × 10 mm i.d., 4.5 mL min^{−1} gradient elution with 2% ACN-H₂O (+0.1% formic acid) over 5 min, then 2% ACN-H₂O (+0.1% formic acid) to 100% ACN (+0.1% formic acid) over 35 min; UV 280 nm) to give pure compounds **5** (tryptamine, 0.4 mg) and the mixture of **6** and **7** ((*E*) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin, 10 mg).

6,6'-bis-(debromo)-gelliusine F (**1**): brown oil, ¹H and ¹³C NMR, see Table 2; HRESIMS *m/z* 319.2015 [M + H]⁺ (calcd for C₂₀H₂₃N₄, 319.1923).

6-bromo-8,1'-dihydro-isoplysin A (**2**): yellow oil, α_D²⁰ 0.0 (*c* 0.5, MeOH); ¹H and ¹³C NMR, see Table 2; HRESIMS *m/z* 337.0483 [M + H]⁺ (calcd for C₁₄H₁₆N₄O⁸¹Br, 337.0487).

5,6-dibromo-8,1'-dihydro-isoplysin A (3): yellow oil, α_D^{20} 0.0 (*c* 0.5, MeOH); ^1H and ^{13}C NMR, see Table 3; HRESIMS m/z 414.9630 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{14}\text{H}_{15}\text{N}_4\text{O}^{79}\text{Br}^{81}\text{Br}$, 414.9592).

3.4. In Vitro Antiplasmodial Assays

Activity against *Plasmodium falciparum* chloroquine-sensitive 3D7 strains was assessed following the procedure already described in Fr  d  rich et al. [18]. The parasites were obtained from MR4-BEI Resources (Manassas, VA, US). Each compound, fraction and extract was applied in a series of eight 2-fold dilutions (final concentrations ranging from 0.8 to 100 $\mu\text{g}/\text{mL}$ for an extract and from 0.08 to 10 $\mu\text{g}/\text{mL}$ for a pure substance) on two rows of a 96-well microplate and were tested in triplicate ($n = 3$). Parasite growth was estimated by determination of lactate dehydrogenase activity as described previously [19]. Artemisinin (98%, Sigma-Aldrich, Saint-Louis, MO, USA) was used as positive control with IC_{50} of 0.006 ± 0.002 $\mu\text{g}/\text{mL}$.

3.5. In Vitro Antimicrobial Assays

All compounds were tested against five marine bacterial strains commonly found on biofilms, *Roseobacter litoralis* (ATCC 495666), *Shewanella putrefaciens* (ATCC 8071), *Vibrio carchariae* (ATCC 35084), *Vibrio natrigens* (ATCC 14048) and *Vibrio proteolyticus* (ATCC 15338). Bacterial adhesion and growth rates were determined according to the methods of Thabard et al. [20], Messina et al. [21] and Trepos et al. [22]. Bacterial suspensions (100 μ aliquots, 2×10^8 colony forming units/mL) were aseptically added to the microplate wells containing compound (0.01–10 $\mu\text{g}/\text{mL}$), and the plates were incubated for 48 h at 26 $^\circ\text{C}$ prior to assessment of bioactivity. Media only (Marine Broth 2216, Difco) was used as a blank. Bacterial growth was monitored spectroscopically at 630 nm. The minimal inhibitory concentration (MIC) for bacterial growth was defined as the lowest concentration which results in a decrease in OD, compared to the blank. The microplates were then emptied, and the bacterial adhesion assay was performed using aqueous crystal staining method [22]. The MIC for bacterial adhesion was defined as the lowest concentration of compound that, after 48-h incubation, produced a decrease of the OD at 595 nm compared to the blank.

4. Conclusions

In conclusion, three new tryptophan derived alkaloids, 6,6'-bis-(debromo)-gelliusine F (1), 6-bromo-8,1'-dihydro-isoplysin A (2) and 5,6-dibromo-8,1'-dihydro-isoplysin A (3), were isolated from *Fascaplysinopsis reticulata* together with four known alkaloids from the same family, 8-oxo-tryptamine (4), tryptamine (5), (*E*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (6) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (7). 6,6'-bis-(debromo)-gelliusine F (1) was a new alkaloid with a bis-tryptamine structure and 6-bromo-8,1'-dihydro-isoplysin A (2) and 5,6-dibromo-8,1'-dihydro-isoplysin A (3) were two new alkaloids with 1',8-dihydroaplysinopsin structure. The 8-oxo-tryptamine (4) and the mixture of the known (*E*) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsin (6, 7) exhibited antiplasmodial activity against *Plasmodium falciparum* with IC_{50} values of 8.8 and 8.0 $\mu\text{g}/\text{mL}$ respectively while 6,6'-bis-(debromo)-gelliusine F (1), 6-bromo-8,1'-dihydro-isoplysin A (2), 5,6-dibromo-8,1'-dihydro-isoplysin A (3) and tryptamine (5) did not show significant antimalarial activity. The two new 6-bromo-8,1'-dihydro-isoplysin A (2) and 5,6-dibromo-8,1'-dihydro-isoplysin A (3) showed promising antifouling activity against *V. natrigens* and tryptamine (5) showed promising antifouling activity against *V. carchariae*. Further isolation, structure elucidation, and structure-activity relationship studies of this type of alkaloids are required for the development of new drugs.

Supplementary Materials: The following are available online at <http://www.mdpi.com/1660-3397/17/3/167/s1>, Figure S1: HRMS spectrum for 6,6'-bis-(debromo)-gelliusine F (1), Figure S2: ^1H NMR (300 MHz, MeOD) spectrum for 6,6'-bis-(debromo)-gelliusine F (1), Figure S3: ^{13}C NMR (300 MHz, MeOD) spectrum for 6,6'-bis-(debromo)-gelliusine F (1), Figure S4: ^1H - ^1H COSY NMR (300 MHz, MeOD) spectrum for 6,6'-bis-(debromo)-gelliusine F (1), Figure S5: HSQC NMR (300 MHz, MeOD) spectrum

for 6,6'-bis-(debromo)-gelliusine F (1), Figure S6: ^1H - ^{13}C HMBC NMR (300 MHz, MeOD) spectrum for 6,6'-bis-(debromo)-gelliusine F (1), Figure S7: HRMS spectrum for 6-bromo-8,1'-dihydro-isoplysin A (2), Figure S8: ^1H NMR (300 MHz, MeOD) spectrum for 6-bromo-8,1'-dihydro-isoplysin A (2), Figure S9: ^{13}C NMR (300 MHz, MeOD) spectrum for 6-bromo-8,1'-dihydro-isoplysin A (2), Figure S10: ^1H - ^1H COSY NMR (300 MHz, MeOD) spectrum for 6-bromo-8,1'-dihydro-isoplysin A (2), Figure S11: HSQC NMR (300 MHz, MeOD) spectrum for 6-bromo-8,1'-dihydro-isoplysin A (2), Figure S12: ^1H - ^{13}C HMBC NMR (300 MHz, MeOD) spectrum for 6-bromo-8,1'-dihydro-isoplysin A (2), Figure S13: HRMS spectrum for 5,6-dibromo-8,1'-dihydro-isoplysin A (3), Figure S14: ^1H NMR (600 MHz, MeOD) spectrum for 5,6-dibromo-8,1'-dihydro-isoplysin A (3), Figure S15: ^{13}C NMR (600 MHz, MeOD) spectrum for 5,6-dibromo-8,1'-dihydro-isoplysin A (3), Figure S16: ^1H NMR (600 MHz, MeOD) spectrum for 8-oxo-tryptamine (4), Figure S17: ^{13}C NMR (600 MHz, MeOD) spectrum for 8-oxo-tryptamine (4), Figure S18: ^1H NMR (300 MHz, MeOD) spectrum for tryptamine (5), Figure S19: ^{13}C NMR (300 MHz, MeOD) spectrum for tryptamine (5), Figure S20: ^1H NMR (500 MHz, DMSO) spectrum for (*E*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsine (6) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsine (7), Figure S21: ^{13}C NMR (500 MHz, MeOD) spectrum for (*E*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsine (6) and (*Z*)-6-bromo-2'-demethyl-3'-*N*-methylaplysinopsine (7).

Author Contributions: A.G.-B. and A.A.-M. designed the project, supervised the whole experiment and prepared the manuscript. E.P., C.M., P.C. and P.-E.C. did the chemical experimental part (extraction, isolation and structural identification of the compounds). P.-E.C. wrote the first draft of the manuscript. The biological assays were designed and performed by R.T. and C.H. for antimicrobial activities, by M.F. for antiplasmodial activity. A.G.-B. organized the sponge collection and the sponge was identified by N.D.V.

Funding: This project was supported by the Regional Council of Reunion Island and the ANR 2011-EBIM-006-01 (ERA-NET Netbiome project POMARE). This publication was also made possible by TASCAR project which is funded by the European Union under grant agreement number 634674.

Acknowledgments: The authors express their gratitude to Prof. M. E. Remanevy for his assistance in sponge collection and C. Debitus, director of research, the coordinator of the project POMARE, for her excellent project management.

Conflicts of Interest: The authors declare no competing financial interest.

References

1. Bialonska, D.; Zjawiony, J.K. Aplysinopsins—Marine Indole Alkaloids: Chemistry, Bioactivity and Ecological Significance. *Mar. Drugs* **2009**, *7*, 166–183. [[CrossRef](#)] [[PubMed](#)]
2. Roll, D.M.; Ireland, C.M.; Lu, H.S.M.; Clardy, J. Fascaplysin, an unusual antimicrobial pigment from the marine sponge *Fascaplysinopsis* sp. *J. Org. Chem.* **1988**, *53*, 3276–3278. [[CrossRef](#)]
3. Segraves, N.L.; Robinson, S.J.; Garcia, D.; Said, S.A.; Fu, X.; Schmitz, F.J.; Pietraszkiewicz, H.; Valeriote, F.A.; Crews, P. Comparison of Fascaplysin and Related Alkaloids: A Study of Structures, Cytotoxicities, and Sources. *J. Nat. Prod.* **2004**, *67*, 783–792. [[CrossRef](#)]
4. Jimenez, C.; Quinoa, E.; Adamczeski, M.; Hunter, L.M.; Crews, P. Novel sponge-derived amino acids. 12. Tryptophan-derived pigments and accompanying sesterterpenes from *Fascaplysinopsis reticulata*. *J. Org. Chem.* **1991**, *56*, 3403–3410. [[CrossRef](#)]
5. Kirsch, G.; König, G.M.; Wright, A.D.; Kaminsky, R. A New Bioactive Sesterterpene and Antiplasmodial Alkaloids from the Marine Sponge *Hyrtios* cf. *erecta*. *J. Nat. Prod.* **2000**, *63*, 825–829. [[CrossRef](#)] [[PubMed](#)]
6. Jiménez, C.; Quiñoá, E.; Crews, P. Novel marine sponge alkaloids 3. β -carbolinium salts from *Fascaplysinopsis reticulata*. *Tetrahedron Lett.* **1991**, *32*, 1843–1846. [[CrossRef](#)]
7. Segraves, N.L.; Lopez, S.; Johnson, T.A.; Said, S.A.; Fu, X.; Schmitz, F.J.; Pietraszkiewicz, H.; Valeriote, F.A.; Crews, P. Structures and cytotoxicities of fascaplysin and related alkaloids from two marine phyla—*Fascaplysinopsis* sponges and *Didemnum* tunicates. *Tetrahedron Lett.* **2003**, *44*, 3471–3475. [[CrossRef](#)]
8. Wang, Q.; Tang, X.; Luo, X.; de Voogd, N.J.; Li, P.; Li, G. (+)- and (–)-Spiroreticulatine, A Pair of Unusual Spiro Bisheterocyclic Quinoline-imidazole Alkaloids from the South China Sea Sponge *Fascaplysinopsis reticulata*. *Org. Lett.* **2015**, *17*, 3458–3461. [[CrossRef](#)]
9. Bodendorf, K.; Walk, A. Darstellung und Reduktion von Indolyl-(3)-aminomethyl-ketonen. *Arch. Pharm.* **1961**, *294*, 484–487. [[CrossRef](#)]
10. Seetham Naidu, P.; Bhuyan, P.J. Synthesis of some analogues of (\pm)gelliusine F, (\pm)gelliusine E, and total synthesis of 2,2-di(6'-bromo-3'-indolyl)ethylamine. *Tetrahedron Lett.* **2012**, *53*, 426–428. [[CrossRef](#)]
11. Bifulco, G.; Bruno, I.; Riccio, R.; Lavayre, J.; Bourdy, G. Further Brominated Bis- and Tris-Indole Alkaloids from the Deep-Water New Caledonian Marine Sponge *Orina* sp. *J. Nat. Prod.* **1995**, *58*, 1254–1260. [[CrossRef](#)]

12. Benbouzid-Rollet, N.D.; Conte, M.; Guezennec, J.; Prieur, D. Monitoring of a *Vibrio natriegens* and *Desulfovibrio vulgaris* marine aerobic biofilm on a stainless steel surface in a laboratory tubular flow system. *J. Appl. Bacteriol.* **1991**, *71*, 244–251. [[CrossRef](#)]
13. Cheng, G.; Li, G.; Xue, H.; Chen, S.; Bryers, J.D.; Jiang, S. Zwitterionic carboxybetaine polymer surfaces and their resistance to long-term biofilm formation. *Biomaterials* **2009**, *30*, 5234–5240. [[CrossRef](#)]
14. Lee, K.K.; Liu, P.C.; Chuang, W.H. Pathogenesis of gastroenteritis caused by *Vibrio carchariae* in cultured marine fish. *Mar. Biotechnol.* **2002**, *4*, 267–277. [[CrossRef](#)]
15. Nicolas, J.L.; Basuyaux, O.; Mazurie, J.; Thebault, A. *Vibrio carchariae*, a pathogen of the abalone *Haliotis tuberculata*. *Dis. Aquat. Org.* **2002**, *50*, 35–43. [[CrossRef](#)]
16. Vandenberghe, J.; Thompson, F.L.; Gomez-Gil, B.; Swings, J. Phenotypic diversity amongst *Vibrio* isolates from marine aquaculture systems. *Aquaculture* **2003**, *219*, 9–20. [[CrossRef](#)]
17. Hu, J.-F.; Schetz, J.A.; Kelly, M.; Peng, J.-N.; Ang, K.K.H.; Flotow, H.; Leong, C.Y.; Ng, S.B.; Buss, A.D.; Wilkins, S.P.; et al. New Antiinfective and Human 5-HT₂ Receptor Binding Natural and Semisynthetic Compounds from the Jamaican Sponge *Smenospongia aurea*. *J. Nat. Prod.* **2002**, *65*, 476–480. [[CrossRef](#)]
18. Frédérich, M.; Jacquier, M.J.; Thepenier, P.; De Mol, P.; Tits, M.; Philippe, G.; Delaude, C.; Angenot, L.; Zeches-Hanrot, M.J. Antiplasmodial activity of alkaloids from various *Strychnos* species. *J. Nat. Prod.* **2002**, *65*, 1381–1386. [[CrossRef](#)]
19. Jonville, M.C.; Dive, G.; Angenot, L.; Bero, J.; Tits, M.; Ollivier, E.; Frédérich, M. Dimeric bisindole alkaloids from the stem bark of *Strychnos nux-vomica* L. *Phytochemistry* **2013**, *87*, 156–163. [[CrossRef](#)]
20. Thabard, M.; Gros, O.; Hellio, C.; Maréchal, J.P. *Sargassum polyceratum* (Phaeophyceae, Fucaceae) surface molecule activity towards fouling organisms and embryonic development of benthic species. *Bot. Mar.* **2011**, *54*, 147–157. [[CrossRef](#)]
21. Messina, C.M.; Renda, G.; Laudicella, V.A.; Trepos, R.; Fauchon, M.; Hellio, C.; Santulli, A. From Ecology to Biotechnology, Study of the Defense Strategies of Algae and Halophytes (from Trapani Saltworks, NW Sicily) with a Focus on Antioxidants and Antimicrobial Properties. *Int. J. Mol. Sci.* **2019**, *20*, 881. [[CrossRef](#)] [[PubMed](#)]
22. Trepos, R.; Cervin, G.; Pile, C.; Pavia, H.; Hellio, C.; Svenson, J. Evaluation of cationic micropeptides derived from the innate immune system as inhibitors of marine biofouling. *Biofouling* **2015**, *31*, 393–403. [[CrossRef](#)] [[PubMed](#)]

